|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 44.99 USD | +1.08% |
|
+0.16% | +60.79% |
| 06-17 | Alkermes' Phase 2 Trial of Alixorexton to Treat Narcolepsy Meets Dual Primary Endpoints | MT |
| 06-15 | Alkermes' Sleep Disorder Drug Receives Orphan Drug Status in US and Europe | MT |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bullish | Bullish | Bullish |
| Resistance | 49.78 | 54.69 | 47.85 |
| Spread/Res. | -9.62% | -17.74% | -5.98% |
| Spread/Supp. | +15.63% | +24.11% | +35.06% |
| Support | 38.91 | 36.25 | 33.31 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- ALKS Stock
- Charts Alkermes plc
Select your edition
All financial news and data tailored to specific country editions
